GHA
REGN icon

GW Henssler & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

GW Henssler & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.5M Sell
23,930
-512
-2% -$392K 0.87% 45
2025
Q4 		$18.9M Buy
24,442
+223
+0.9% +$151K 0.91% 44
2025
Q3 		$13.6M Buy
24,219
+2,737
+13% +$1.55M 0.68% 61
2025
Q2 		$11.3M Buy
21,482
+1,122
+6% +$626K 0.6% 69
2025
Q1 		$12.9M Buy
20,360
+2,543
+14% +$1.75M 0.74% 59
2024
Q4 		$18.7M Sell
17,817
-251
-1% -$211K 1.07% 41
2024
Q3 		$19M Sell
18,068
-477
-3% -$531K 1.07% 41
2024
Q2 		$19.5M Sell
18,545
-908
-5% -$880K 1.17% 38
2024
Q1 		$18.7M Sell
19,453
-498
-2% -$474K 1.1% 42
2023
Q4 		$17.5M Sell
19,951
-528
-3% -$435K 1.16% 39
2023
Q3 		$16.9M Sell
20,479
-425
-2% -$334K 1.15% 38
2023
Q2 		$15M Sell
20,904
-198
-0.9% -$153K 0.99% 48
2023
Q1 		$17.3M Sell
21,102
-190
-0.9% -$143K 1.15% 42
2022
Q4 		$15.4M Buy
21,292
+410
+2% +$303K 1.08% 40
2022
Q3 		$14.4M Buy
20,882
+411
+2% +$259K 1.08% 41
2022
Q2 		$12.1M Buy
20,471
+55
+0.3% +$35.8K 0.9% 49
2022
Q1 		$14.3M Buy
20,416
+370
+2% +$234K 0.87% 50
2021
Q4 		$12.7M Buy
20,046
+134
+0.7% +$82.4K 0.81% 55
2021
Q3 		$12.1M Buy
19,912
+60
+0.3% +$37.2K 0.84% 55
2021
Q2 		$11.1M Buy
19,852
+490
+3% +$248K 0.73% 61
2021
Q1 		$9.16M Buy
19,362
+883
+5% +$430K 0.66% 63
2020
Q4 		$8.93M Sell
18,479
-1,799
-9% -$971K 0.68% 58
2020
Q3 		$11.4M Sell
20,278
-13,744
-40% -$8.33M 0.96% 50
2020
Q2 		$21.2M Sell
34,022
-2,916
-8% -$1.66M 1.87% 10
2020
Q1 		$18M Sell
36,938
-1,018
-3% -$420K 1.83% 12
2019
Q4 		$14.3M Buy
37,956
+1,835
+5% +$617K 1.18% 32
2019
Q3 		$10M Buy
36,121
+8,382
+30% +$2.48M 0.89% 47
2019
Q2 		$8.68M Buy
+27,739
New +$9.23M 0.79% 55

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

GW Henssler & Associates's REGN Position: Q1 2026 in Review

GW Henssler & Associates reduced its Regeneron Pharmaceuticals (REGN) stake by 2.1% in Q1 2026, selling an estimated $392K and leaving 23,930 shares worth $18.5M. The position accounts for 0.87% of the portfolio, ranked #45.

GW Henssler & Associates first reported a position in REGN in Q2 2019 and has held it in 28 quarters since. The position peaked at $21.2M in Q2 2020. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • GW Henssler & Associates held 23,930 shares of Regeneron Pharmaceuticals worth $18.5M as of Q1 2026.
  • GW Henssler & Associates sold 512 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $392K.
  • Regeneron Pharmaceuticals made up 0.87% of GW Henssler & Associates's portfolio in Q1 2026, its #45 holding.
  • GW Henssler & Associates first reported a position in Regeneron Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
  • GW Henssler & Associates's Regeneron Pharmaceuticals position peaked at $21.2M in Q2 2020.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on GW Henssler & Associates's 13F filing for Q1 2026, filed 15 May 2026.